SCHEDULE: Kiora Pharma: ADAR1 Group Reports 9.9% Stake

ADAR1 Capital Management, its general partner, and Daniel Schneeberger collectively report a 9.9% beneficial ownership stake in Kiora Pharmaceuticals, Inc. as of June 30, 2025.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger collectively reported beneficial ownership in Kiora Pharmaceuticals, Inc.
• As of June 30, 2025, ADAR1 Capital Management, LLC and Daniel Schneeberger each beneficially owned 362,527 shares of Common Stock, representing 9.9% of the class.
• ADAR1 Capital Management GP, LLC beneficially owned 365,179 shares of Common Stock, also representing 9.9% of the class.
• The beneficial ownership for ADAR1 Capital Management, LLC and Daniel Schneeberger includes 143,223 shares of common stock held by ADAR1 Partners, LP, 23,888 shares held by Spearhead Insurance Solutions IDF, LLC, and 195,416 shares underlying pre-funded and milestone warrants held by ADAR1 Partners, LP.
• The beneficial ownership for ADAR1 Capital Management GP, LLC includes 143,223 shares of common stock held by ADAR1 Partners, LP and 221,956 shares underlying pre-funded and milestone warrants held by ADAR1 Partners, LP.
• All reported percentages are capped at 9.9% due to beneficial ownership limitations of 9.99% on the exchange and exercise of certain warrants.
• The total outstanding shares of Kiora Pharmaceuticals, Inc. Common Stock used for calculation were 3,433,491 as of June 30, 2025, as reported in the Issuer's 10-Q filed on August 8, 2025.

Sentiment

Score: 5

Explanation: The filing is a standard beneficial ownership report (Schedule 13G) and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or prospects. It simply reports a significant ownership stake by an investment group.

Positives

• An investment group, ADAR1 Capital Management, holds a significant 9.9% beneficial ownership stake in Kiora Pharmaceuticals, Inc., indicating a notable institutional interest.

Negatives

• NA

Risks

• The filing mentions beneficial ownership limitations (9.99%) on the exchange and exercise of pre-funded and milestone warrants, which could limit the immediate conversion of a larger potential stake.

Future Outlook

NA

Industry Context

This filing indicates an institutional investor's significant stake in a pharmaceutical company. Such investments are common in the biotech/pharma sector, where long-term capital is often required for R&D and clinical trials. A 9.9% stake suggests a substantial, but not controlling, interest, often seen as a vote of confidence in the company's long-term prospects or a strategic investment.

Comparison to Industry Standards

• A 9.9% beneficial ownership stake by an investment group like ADAR1 Capital Management is a significant position for a single entity in a publicly traded pharmaceutical company, often signaling strong conviction in the company's valuation or future potential.
• The use of pre-funded and milestone warrants, subject to beneficial ownership limitations, is a common strategy for institutional investors to acquire a large potential stake while staying below certain reporting thresholds or avoiding triggering control-related provisions.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.9% stake by an institutional investor (ADAR1 Capital Management) may be viewed positively, potentially signaling confidence in Kiora Pharmaceuticals' future.
• Management: Awareness of a large institutional holder may influence strategic decisions, though the filing explicitly states the shares were not acquired for the purpose of changing or influencing control.

Key Dates

Keywords

Kiora Pharmaceuticals, ADAR1 Capital Management, Daniel Schneeberger, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, SEC Filing, Pharmaceutical